INFLARX N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.46 USD | +1.39% |
|
-3.95% | -10.43% |
| 05-08 | InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 03-21 | Transcript : InflaRx N.V. - Special Call |
Presenter SpeechTessa Romero (Analysts)Okay, good morning. Great. I think we will kick this of...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Calendar
2024-06-05
- R&D Day
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.342
EUR
Average target price
8.375
EUR
Spread / Average Target
+523.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.43% | 85.97M | |
| +9.83% | 115B | |
| +10.80% | 105B | |
| -10.84% | 22.71B | |
| -1.69% | 21.83B | |
| -10.51% | 18.18B | |
| -41.92% | 16.52B | |
| -15.11% | 16.01B | |
| +6.62% | 14.14B | |
| +17.53% | 10.71B |
- Stock Market
- Equities
- IFRX Stock
- News InflaRx N.V.
- Transcript : InflaRx N.V. Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-10-2018 08
